Adipotide (FTPP)

Adipotide (FTPP - Fat Targeting Proapoptotic Peptide) is a chimeric peptide developed at MD Anderson Cancer Center that produces targeted destruction of the vasculature supplying white adipose tissue (WAT), resulting in fat cell death through ischaemic apoptosis. Its mechanism is fundamentally different from all other weight loss peptides - rather than reducing appetite or altering metabolism, it literally dismantles the blood supply that keeps fat cells alive.

The peptide's design is ingenious: it consists of two domains linked together. A targeting domain (CKGGRAKDC) that binds specifically to prohibitin expressed on the surface of white adipose tissue blood vessels, and a pro-apoptotic domain (KLAKLAK)₂ that disrupts mitochondrial membranes upon cellular internalisation. When adipotide reaches circulation, the targeting domain homes specifically to the vasculature of WAT - the peptide then penetrates into endothelial cells, where the KLAKLAK domain triggers mitochondrial disruption and apoptotic cell death. Without blood supply, the surrounding adipocytes undergo ischaemic apoptosis and are cleared by the immune system.

The selectivity of this targeting mechanism is remarkable. Despite the aggressive cytotoxic payload, the peptide preferentially accumulates in WAT vasculature rather than other tissues, due to the differential expression of prohibitin on adipose versus non-adipose endothelium. This selectivity has been validated in multiple rodent and primate models.

The landmark primate study published in Science Translational Medicine in 2011 remains the most cited research on adipotide. Obese rhesus monkeys treated for 28 days showed average weight loss of 11% with significant reduction in both subcutaneous and visceral fat. Importantly, this occurred without dietary restriction - the primates were fed ad libitum throughout. Insulin sensitivity improved beyond what weight loss alone would predict, suggesting additional metabolic effects.

The Achilles heel of adipotide research has been renal toxicity. In the primate study, some animals showed elevated serum creatinine and BUN, indicating transient kidney stress. This appears to be reversible upon cessation but has been the primary obstacle to human clinical translation. Research continues into modified versions with improved renal safety profiles.

Adipotide represents a fascinating proof of concept for "vascular targeting" approaches to adipose tissue reduction - a fundamentally different paradigm from the appetite-suppressing and metabolic-enhancing approaches of GLP-1 agents.